These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37008539)

  • 21. Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone.
    Hagiwara M; Panjabi S; Sharma A; Delea TE
    J Med Econ; 2019 Aug; 22(8):818-829. PubMed ID: 31046501
    [No Abstract]   [Full Text] [Related]  

  • 22. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
    Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
    Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
    McBride A; Klaus JO; Stockerl-Goldstein K
    Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Observation and Mitigation of Lamellar Silica Particles Formed in Pharmaceutical Products Packaged in Glass Vials.
    Nashed-Samuel Y; Gastwirt J; Kotia RB; Moore S; Masatani P; Torraca G; Goss M; Dolan DG; Akers M; Padala C; Wypych J; Semin DJ
    J Pharm Sci; 2022 Dec; 111(12):3275-3286. PubMed ID: 36116524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Leachable Study of Glass Vials to Demonstrate the Impact of Low Fill Volume.
    Hladik B; Buscke F; Frost R; Rothhaar U
    PDA J Pharm Sci Technol; 2019; 73(4):345-355. PubMed ID: 30770482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A;
    N Engl J Med; 2015 Jan; 372(2):142-52. PubMed ID: 25482145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
    Davies F; Rifkin R; Costello C; Morgan G; Usmani S; Abonour R; Palumbo A; Romanus D; Hajek R; Terpos E; Cherepanov D; Stull DM; Huang H; Leleu X; Berdeja J; Lee HC; Weisel K; Thompson M; Boccadoro M; Zonder J; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A
    Ann Hematol; 2021 Sep; 100(9):2325-2337. PubMed ID: 33970288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of surface properties of glass vials used as primary packaging material for parenterals.
    Ditter D; Mahler HC; Roehl H; Wahl M; Huwyler J; Nieto A; Allmendinger A
    Eur J Pharm Biopharm; 2018 Apr; 125():58-67. PubMed ID: 29331438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma.
    Bhutani D; Zonder JA
    Blood Lymphat Cancer; 2017; 7():53-60. PubMed ID: 31360084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
    J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carfilzomib boosted combination therapy for relapsed multiple myeloma.
    Steiner RE; Manasanch EE
    Onco Targets Ther; 2017; 10():895-907. PubMed ID: 28243125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carfilzomib for relapsed and refractory multiple myeloma.
    Groen K; van de Donk N; Stege C; Zweegman S; Nijhof IS
    Cancer Manag Res; 2019; 11():2663-2675. PubMed ID: 31037034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
    Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
    Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.
    Kraus M; Bader J; Overkleeft H; Driessen C
    Blood Cancer J; 2013 Mar; 3(3):e103. PubMed ID: 23454896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
    Moreau P; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Risse ML; Asset G; Macé S; Martin T;
    Lancet; 2021 Jun; 397(10292):2361-2371. PubMed ID: 34097854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM).
    Hájek R; Bryce R; Ro S; Klencke B; Ludwig H
    BMC Cancer; 2012 Sep; 12():415. PubMed ID: 22992303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Noninvasive identification of materials inside USP vials with Raman spectroscopy and a Raman spectral library.
    McCreery RL; Horn AJ; Spencer J; Jefferson E
    J Pharm Sci; 1998 Jan; 87(1):1-8. PubMed ID: 9452960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.